Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCT vs SOC in Oligoprogressive NSCLC on ICI
NCT04485026Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2020
- Primary completion
- May 2024
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Overall Survival at 3 years. Planned start Nov 2020; status: withdrawn.
Beyond the preview
Go deeper on NCT04485026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485026.